{"entity":{"id":"nct06137118","kind":"trial","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","aka":[],"tldr":"A phase 1/2 trial of Surovatamig in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.","summary":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia is a phase 1/2 interventional study registered as NCT06137118 by AstraZeneca, with 255 participants planned, started 2023-12-29 and due to reach its primary completion in 2028-02-11. Interventions recorded: Surovatamig.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06137118","url":"https://clinicaltrials.gov/study/NCT06137118"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06137118","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia","sponsor":"AstraZeneca","enrolled":255,"outcomes":[]},"route":"/trials/nct06137118/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}